{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:49:33Z","timestamp":1776142173398,"version":"3.50.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s00467-010-1739-z","type":"journal-article","created":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T23:18:14Z","timestamp":1295997494000},"page":"2111-2119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Can bisphosphonates play a role in the treatment of children with chronic kidney disease?"],"prefix":"10.1007","volume":"26","author":[{"given":"Dieter","family":"Haffner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar-Christiane","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,1]]},"reference":[{"key":"1739_CR1","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","volume":"32","author":"RN Foley","year":"1998","unstructured":"Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112\u2013S119","journal-title":"Am J Kidney Dis"},{"key":"1739_CR2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/01.CIR.0000020222.63035.C0","volume":"106","author":"J Oh","year":"2002","unstructured":"Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100\u2013105","journal-title":"Circulation"},{"key":"1739_CR3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00467-006-0359-0","volume":"23","author":"MM Mitsnefes","year":"2008","unstructured":"Mitsnefes MM (2008) Cardiovascular complications of pediatric chronic kidney disease. Pediatr Nephrol 23:27\u201339","journal-title":"Pediatr Nephrol"},{"key":"1739_CR4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1067\/mpd.2002.125910","volume":"141","author":"RS Parekh","year":"2002","unstructured":"Parekh RS, Carroll CE, Wolfe RA, Port FK (2002) Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141:191\u2013197","journal-title":"J Pediatr"},{"key":"1739_CR5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00198-006-0282-z","volume":"18","author":"LC Hofbauer","year":"2007","unstructured":"Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H (2007) Vascular calcification and osteoporosis\u2014from clinical observation towards molecular understanding. Osteoporos Int 18:251\u2013259","journal-title":"Osteoporos Int"},{"key":"1739_CR6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","volume":"94","author":"WA Peck","year":"1993","unstructured":"Peck WA, Burckhardt P, Christiansen C, Fleisch HA, Genant HK, Gennari C, Martin TJ, Martini L, Morita R, Ogata E, Rapado A, Shulman LE, Stern PH, Young RTT (1993) Consensus Development Conference\u2014Diagnosis, Prophylaxis, and Treatment of Osteoporosis. Am J Med 94:646\u2013650","journal-title":"Am J Med"},{"key":"1739_CR7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137\u20131141","journal-title":"J Bone Miner Res"},{"key":"1739_CR8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/B978-012286551-0\/50019-1","volume-title":"Pediatric bone biology and disease","author":"LM Ward","year":"2003","unstructured":"Ward LM, Glorieux FH (2003) The spectrum of pediatric osteoporosis. In: Glorieux FH, Pettifor JM, J\u00fcppner H (eds) Pediatric bone biology and disease, vol 1. Elsevier Science, San Diego, pp 401\u2013442"},{"key":"1739_CR9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00467-009-1318-3","volume":"25","author":"R Grenda","year":"2010","unstructured":"Grenda R (2010) Effects of steroid avoidance and novel protocols on growth in paediatric renal transplant patients. Pediatr Nephrol 25:747\u2013752","journal-title":"Pediatr Nephrol"},{"key":"1739_CR10","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00223-001-0043-0","volume":"70","author":"ML Bianchi","year":"2002","unstructured":"Bianchi ML (2002) Glucorticoids and bone: some general remarks and some special observations in pediatric patients. Calcif Tissue Int 70:384\u2013390","journal-title":"Calcif Tissue Int"},{"issue":"Suppl 2","key":"1739_CR11","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1542\/peds.2006-2023J","volume":"119","author":"MB Leonard","year":"2007","unstructured":"Leonard MB (2007) Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 119 [Suppl 2]:S166\u2013S174","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"1739_CR12","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1530\/EJE-08-0282","volume":"159","author":"NJ Shaw","year":"2008","unstructured":"Shaw NJ (2008) Management of osteoporosis in children. Eur J Endocrinol 159 [Suppl 1]:S33\u2013S39","journal-title":"Eur J Endocrinol"},{"key":"1739_CR13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.ackd.2006.10.005","volume":"14","author":"SM Moe","year":"2007","unstructured":"Moe SM, Drueke T, Lameire N, Eknoyan G (2007) Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chron Kidney Dis 14:3\u201312","journal-title":"Adv Chron Kidney Dis"},{"key":"1739_CR14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00467-009-1337-0","volume":"25","author":"KA Hruska","year":"2010","unstructured":"Hruska KA, Choi ET, Memon I, Davis TK, Mathew S (2010) Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol 25:769\u2013778","journal-title":"Pediatr Nephrol"},{"key":"1739_CR15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1399-3046.2004.00191.x","volume":"8","author":"AA El-Husseini","year":"2004","unstructured":"El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA, Ghoneim MA (2004) Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant 8:357\u2013361","journal-title":"Pediatr Transplant"},{"issue":"Suppl 2","key":"1739_CR16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2362.2006.01662.x","volume":"36","author":"K Kodras","year":"2006","unstructured":"Kodras K, Haas M (2006) Effect of kidney transplantation on bone. Eur J Clin Invest 36 [Suppl 2]:63\u201375","journal-title":"Eur J Clin Invest"},{"key":"1739_CR17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ki.2008.264","volume":"74","author":"TL Nickolas","year":"2008","unstructured":"Nickolas TL, Leonard MB, Shane E (2008) Chronic kidney disease and bone fracture: a growing concern. Kidney Int 74:721\u2013731","journal-title":"Kidney Int"},{"key":"1739_CR18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00467-009-1248-0","volume":"25","author":"LT Weber","year":"2010","unstructured":"Weber LT, Mehls O (2010) Limitations of dual x-ray absorptiometry in children with chronic kidney disease. Pediatr Nephrol 25:3\u20135","journal-title":"Pediatr Nephrol"},{"key":"1739_CR19","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032\u20131045","journal-title":"Mayo Clin Proc"},{"key":"1739_CR20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","volume":"19","author":"H Fleisch","year":"1998","unstructured":"Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19:80\u2013100","journal-title":"Endocr Rev"},{"issue":"Suppl 4","key":"1739_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","volume":"9","author":"JR Green","year":"2004","unstructured":"Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9 [Suppl 4]:3\u201313","journal-title":"Oncologist"},{"key":"1739_CR22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ki.2008.646","volume":"75","author":"KA Lomashvili","year":"2009","unstructured":"Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O\u2019Neill WC (2009) Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 75:617\u2013625","journal-title":"Kidney Int"},{"key":"1739_CR23","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ki.2008.663","volume":"75","author":"EG Neven","year":"2009","unstructured":"Neven EG, De Broe ME, D\u2019Haese PC (2009) Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? Kidney Int 75:580\u2013582","journal-title":"Kidney Int"},{"key":"1739_CR24","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1093\/jn\/131.11.2910","volume":"131","author":"PA Price","year":"2001","unstructured":"Price PA, Buckley JR, Williamson MK (2001) The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131:2910\u20132915","journal-title":"J Nutr"},{"key":"1739_CR25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.ATV.21.5.817","volume":"21","author":"PA Price","year":"2001","unstructured":"Price PA, Faus SA, Williamson MK (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21:817\u2013824","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1739_CR26","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00223-002-1006-9","volume":"71","author":"PA Price","year":"2002","unstructured":"Price PA, Omid N, Than TN, Williamson MK (2002) The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 71:356\u2013363","journal-title":"Calcif Tissue Int"},{"key":"1739_CR27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2215\/CJN.02550508","volume":"4","author":"ND Toussaint","year":"2009","unstructured":"Toussaint ND, Elder GJ, Kerr PG (2009) Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 4:221\u2013233","journal-title":"Clin J Am Soc Nephrol"},{"key":"1739_CR28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","volume":"56","author":"ND Toussaint","year":"2010","unstructured":"Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG (2010) Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 56:57\u201368","journal-title":"Am J Kidney Dis"},{"key":"1739_CR29","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.165.3899.1262","volume":"165","author":"H Fleisch","year":"1969","unstructured":"Fleisch H, Russell RG, Francis MD (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262\u20131264","journal-title":"Science"},{"issue":"Suppl 2","key":"1739_CR30","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1542\/peds.2006-2023H","volume":"119","author":"RG Russell","year":"2007","unstructured":"Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119 [Suppl 2]:S150\u2013S162","journal-title":"Pediatrics"},{"key":"1739_CR31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RG Russell","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733\u2013759","journal-title":"Osteoporos Int"},{"key":"1739_CR32","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/sj.ki.5001841","volume":"70","author":"PA Price","year":"2006","unstructured":"Price PA, Roublick AM, Williamson MK (2006) Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 70:1577\u20131583","journal-title":"Kidney Int"},{"key":"1739_CR33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1254\/jphs.FPJ05019X","volume":"99","author":"K Tamura","year":"2005","unstructured":"Tamura K, Suzuki Y, Hashiba H, Tamura H, Aizawa S, Kogo H (2005) Effect of etidronate on aortic calcification and bone metabolism in calcitoriol-treated rats with subtotal nephrectomy. J Pharmacol Sci 99:89\u201394","journal-title":"J Pharmacol Sci"},{"key":"1739_CR34","first-page":"174","volume":"5","author":"A Tomat","year":"2005","unstructured":"Tomat A, Gamba CA, Mandalunis P, De Grandi MC, Somoza J, Friedman S, Zeni S (2005) Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease. J Musculoskelet Neuronal Interact 5:174\u2013181","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"1739_CR35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1440-1754.2005.00718.x","volume":"41","author":"JJ Brown","year":"2005","unstructured":"Brown JJ, Zacharin MR (2005) Proposals for prevention and management of steroid-induced osteoporosis in children and adolescents. J Paediatr Child Health 41:553\u2013557","journal-title":"J Paediatr Child Health"},{"key":"1739_CR36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12178-009-9046-7","volume":"2","author":"HL Wright","year":"2009","unstructured":"Wright HL, McCarthy HS, Middleton J, Marshall MJ (2009) RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2:56\u201364","journal-title":"Curr Rev Musculoskelet Med"},{"key":"1739_CR37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000166209","volume":"55","author":"P Pietschmann","year":"2009","unstructured":"Pietschmann P, Rauner M, Sipos W, Kerschan-Schindl K (2009) Osteoporosis: an age-related and gender-specific disease\u2014a mini-review. Gerontology 55:3\u201312","journal-title":"Gerontology"},{"key":"1739_CR38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000276666","volume":"29","author":"R Amerling","year":"2010","unstructured":"Amerling R, Harbord NB, Pullman J, Feinfeld DA (2010) Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif 29:293\u2013299","journal-title":"Blood Purif"},{"key":"1739_CR39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00467-009-1249-z","volume":"25","author":"ML Bianchi","year":"2010","unstructured":"Bianchi ML, Baim S, Bishop NJ, Gordon CM, Hans DB, Langman CB, Leonard MB, Kalkwarf HJ (2010) Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatr Nephrol 25:37\u201347","journal-title":"Pediatr Nephrol"},{"key":"1739_CR40","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s00467-007-0490-6","volume":"22","author":"MB Leonard","year":"2007","unstructured":"Leonard MB (2007) A structural approach to the assessment of fracture risk in children and adolescents with chronic kidney disease. Pediatr Nephrol 22:1815\u20131824","journal-title":"Pediatr Nephrol"},{"key":"1739_CR41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1525-139X.2007.00271.x","volume":"20","author":"PD Miller","year":"2007","unstructured":"Miller PD (2007) Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 20:186\u2013190","journal-title":"Semin Dial"},{"key":"1739_CR42","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1097\/01.ASN.0000087092.53894.80","volume":"14","author":"M Coco","year":"2003","unstructured":"Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, Tellis V, Greenstein S, Schechner R, Figueroa K, McDonough P, Wang G, Malluche H (2003) Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 14:2669\u20132676","journal-title":"J Am Soc Nephrol"},{"key":"1739_CR43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00041552-200109000-00006","volume":"10","author":"SL Fan","year":"2001","unstructured":"Fan SL, Cunningham J (2001) Bisphosphonates in renal osteodystrophy. Curr Opin Nephrol Hypertens 10:581\u2013588","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1739_CR44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00044011-200626040-00006","volume":"26","author":"T Ariyoshi","year":"2006","unstructured":"Ariyoshi T, Eishi K, Sakamoto I, Matsukuma S, Odate T (2006) Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig 26:215\u2013222","journal-title":"Clin Drug Investig"},{"key":"1739_CR45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1744-9987.2006.00345.x","volume":"10","author":"H Hashiba","year":"2006","unstructured":"Hashiba H, Aizawa S, Tamura K, Kogo H (2006) Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Ther Apher Dial 10:59\u201364","journal-title":"Ther Apher Dial"},{"key":"1739_CR46","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s004670050546","volume":"12","author":"E Sellers","year":"1998","unstructured":"Sellers E, Sharma A, Rodd C (1998) The use of pamidronate in three children with renal disease. Pediatr Nephrol 12:778\u2013781","journal-title":"Pediatr Nephrol"},{"key":"1739_CR47","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/adc.2003.036590","volume":"90","author":"NJ Shaw","year":"2005","unstructured":"Shaw NJ, Bishop NJ (2005) Bisphosphonate treatment of bone disease. Arch Dis Child 90:494\u2013499","journal-title":"Arch Dis Child"},{"key":"1739_CR48","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1525-139X.2007.00263.x","volume":"20","author":"NM Rogers","year":"2007","unstructured":"Rogers NM, Teubner DJ, Coates PT (2007) Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dial 20:150\u2013157","journal-title":"Semin Dial"},{"key":"1739_CR49","first-page":"1","volume":"843","author":"WHO","year":"1994","unstructured":"WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1\u2013129","journal-title":"World Health Organ Tech Rep Ser"},{"key":"1739_CR50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jocd.2007.12.003","volume":"11","author":"F Rauch","year":"2008","unstructured":"Rauch F, Plotkin H, DiMeglio L, Engelbert RH, Henderson RC, Munns C, Wenkert D, Zeitler P (2008) Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2007 Pediatric Official Positions. J Clin Densitom 11:22\u201328","journal-title":"J Clin Densitom"},{"key":"1739_CR51","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1034\/j.1600-6143.2001.001003243.x","volume":"1","author":"JM Saland","year":"2001","unstructured":"Saland JM, Goode ML, Haas DL, Romano TA, Seikaly MG (2001) The prevalence of osteopenia in pediatric renal allograft recipients varies with the method of analysis. Am J Transplant 1:243\u2013250","journal-title":"Am J Transplant"},{"key":"1739_CR52","first-page":"S1","volume":"42","author":"K\/DOQI","year":"2003","unstructured":"K\/DOQI (2003) Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1\u2013S201","journal-title":"Am J Kidney Dis"},{"key":"1739_CR53","first-page":"S1","volume":"46","author":"K\/DOQI","year":"2005","unstructured":"K\/DOQI (2005) Clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46:S1\u2013S103","journal-title":"Am J Kidney Dis"},{"key":"1739_CR54","doi-asserted-by":"publisher","unstructured":"Christoforidis A, Printza N, Gkogka C, Siomou E, Challa A, Kazantzidou E, Kollios K, Papachristou F (2010) Comparative study of quantitative ultrasonography and dual-energy X-ray absorptiometry for evaluating renal osteodystrophy in children with chronic kidney disease. J Bone Miner Metab. doi:https:\/\/doi.org\/10.1007\/s00774-010-0220-1","DOI":"10.1007\/s00774-010-0220-1"},{"key":"1739_CR55","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1515\/CCLM.2008.310","volume":"46","author":"PM Camacho","year":"2008","unstructured":"Camacho PM, Lopez NA (2008) Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis. Clin Chem Lab Med 46:1345\u20131357","journal-title":"Clin Chem Lab Med"},{"key":"1739_CR56","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1210\/jc.2006-1706","volume":"92","author":"M Rauchenzauner","year":"2007","unstructured":"Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, Finkenstedt G, H\u00f6gler W (2007) Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2\u00a0months to 18\u00a0years. J Clin Endocrinol Metab 92:443\u2013449","journal-title":"J Clin Endocrinol Metab"},{"key":"1739_CR57","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3949\/ccjm.75.10.739","volume":"75","author":"FR Singer","year":"2008","unstructured":"Singer FR, Eyre DR (2008) Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 75:739\u2013750","journal-title":"Cleve Clin J Med"},{"key":"1739_CR58","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s001980070116","volume":"11","author":"P Szulc","year":"2000","unstructured":"Szulc P, Seeman E, Delmas PD (2000) Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 11:281\u2013294","journal-title":"Osteoporos Int"},{"key":"1739_CR59","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/archpedi.160.10.1026","volume":"160","author":"KJ Loud","year":"2006","unstructured":"Loud KJ, Gordon CM (2006) Adolescent bone health. Arch Pediatr Adolesc Med 160:1026\u20131032","journal-title":"Arch Pediatr Adolesc Med"},{"key":"1739_CR60","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00467-004-1790-8","volume":"20","author":"PD Acott","year":"2005","unstructured":"Acott PD, Wong JA, Lang BA, Crocker JF (2005) Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol 20:368\u2013373","journal-title":"Pediatr Nephrol"},{"key":"1739_CR61","doi-asserted-by":"crossref","first-page":"c81","DOI":"10.1159\/000089664","volume":"102","author":"SD Kim","year":"2006","unstructured":"Kim SD, Cho BS (2006) Pamidronate therapy for preventing steroid-induced osteoporosis in children with nephropathy. Nephron Clin Pract 102:c81\u2013c87","journal-title":"Nephron Clin Pract"},{"key":"1739_CR62","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/rheumatology\/keh538","volume":"44","author":"S Rudge","year":"2005","unstructured":"Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T (2005) Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatol (Oxf) 44:813\u2013818","journal-title":"Rheumatol (Oxf)"},{"key":"1739_CR63","doi-asserted-by":"crossref","unstructured":"Ward LM, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury, Rauch F, Tugwell P, Moher D (2007) Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev CD005324","DOI":"10.1002\/14651858.CD005324.pub2"},{"key":"1739_CR64","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1046\/j.1523-1755.2000.t01-1-00890.x","volume":"57","author":"SL Fan","year":"2000","unstructured":"Fan SL, Almond MK, Ball E, Evans K, Cunningham J (2000) Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57:684\u2013690","journal-title":"Kidney Int"},{"key":"1739_CR65","doi-asserted-by":"crossref","unstructured":"Palmer SC, McGregor DO, Strippoli GF (2007) Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev CD005015","DOI":"10.1002\/14651858.CD005015.pub3"},{"key":"1739_CR66","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/ndt\/gfl567","volume":"22","author":"N Fujii","year":"2007","unstructured":"Fujii N, Hamano T, Mikami S, Nagasawa Y, Isaka Y, Moriyama T, Horio M, Imai E, Hori M, Ito T (2007) Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). Nephrol Dial Transplant 22:1601\u20131607","journal-title":"Nephrol Dial Transplant"},{"key":"1739_CR67","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/ndt\/gfl568","volume":"22","author":"Y Kikuchi","year":"2007","unstructured":"Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Kushiyama T, Higashi K, Hyodo N, Yamamoto K, Suzuki S, Miura S (2007) Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease. Nephrol Dial Transplant 22:1593\u20131600","journal-title":"Nephrol Dial Transplant"},{"key":"1739_CR68","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1526-0968.2004.00136.x","volume":"8","author":"H Hashiba","year":"2004","unstructured":"Hashiba H, Aizawa S, Tamura K, Shigematsu T, Kogo H (2004) Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther Apher Dial 8:241\u2013247","journal-title":"Ther Apher Dial"},{"key":"1739_CR69","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0272-6386(04)00937-0","volume":"44","author":"K Nitta","year":"2004","unstructured":"Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H (2004) Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44:680\u2013688","journal-title":"Am J Kidney Dis"},{"key":"1739_CR70","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/jc.2008-1531","volume":"94","author":"LK Bachrach","year":"2009","unstructured":"Bachrach LK, Ward LM (2009) Clinical review: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 94:400\u2013409","journal-title":"J Clin Endocrinol Metab"},{"key":"1739_CR71","first-page":"175","volume":"45","author":"CE Machado","year":"1996","unstructured":"Machado CE, Flombaum CD (1996) Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 45:175\u2013179","journal-title":"Clin Nephrol"},{"key":"1739_CR72","doi-asserted-by":"crossref","unstructured":"Torregrosa JV, Moreno A, Mas M, Ybarra J, Fuster D (2003) Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. Kidney Int Suppl S88\u2013S90","DOI":"10.1046\/j.1523-1755.63.s85.21.x"},{"key":"1739_CR73","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/j.1552-4604.1997.tb04304.x","volume":"37","author":"JR Berenson","year":"1997","unstructured":"Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, Seaman JJ (1997) Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 37:285\u2013290","journal-title":"J Clin Pharmacol"},{"key":"1739_CR74","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/0091270007301801","volume":"47","author":"R Bergner","year":"2007","unstructured":"Bergner R, Henrich DM, Hoffmann M, Honecker A, Mikus G, Nauth B, Nagel D, Uppenkamp M (2007) Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. J Clin Pharmacol 47:942\u2013950","journal-title":"J Clin Pharmacol"},{"key":"1739_CR75","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1093\/ndt\/10.12.2266","volume":"10","author":"AE Beigel","year":"1995","unstructured":"Beigel AE, Rienhoff E, Olbricht CJ (1995) Removal of clodronate by haemodialysis in end-stage renal disease patients. Nephrol Dial Transplant 10:2266\u20132268","journal-title":"Nephrol Dial Transplant"},{"key":"1739_CR76","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/ndt\/17.7.1281","volume":"17","author":"R Bergner","year":"2002","unstructured":"Bergner R, Dill K, Boerner D, Uppenkamp M (2002) Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. Nephrol Dial Transplant 17:1281\u20131285","journal-title":"Nephrol Dial Transplant"},{"key":"1739_CR77","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1440-1797.2006.00569.x","volume":"11","author":"M Buttazzoni","year":"2006","unstructured":"Buttazzoni M, Rosa Diez GJ, Jager V, Crucelegui MS, Algranati SL, Plantalech L (2006) Elimination and clearance of pamidronate by haemodialysis. Nephrology (Carlton) 11:197\u2013200","journal-title":"Nephrology (Carlton)"},{"key":"1739_CR78","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s001120050556","volume":"148","author":"F Rauch","year":"2000","unstructured":"Rauch F, Schonau E, Glorieux FH (2000) Bisphosphonates\u2014pediatric use. Monatsschr Kinderheilkd 148:334\u2013341","journal-title":"Monatsschr Kinderheilkd"},{"key":"1739_CR79","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.beem.2008.07.001","volume":"22","author":"SE Papapoulos","year":"2008","unstructured":"Papapoulos SE (2008) Bisphosphonates: how do they work? Best Pract Res Clin Endocrinol Metab 22:831\u2013847","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1739_CR80","first-page":"273","volume":"62","author":"D Haffner","year":"2010","unstructured":"Haffner D, Fischer DC (2010) Bone cell biology and pediatric renal osteodystrophy. Minerva Pediatr 62:273\u2013284","journal-title":"Minerva Pediatr"},{"key":"1739_CR81","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00467-010-1660-5","volume":"26","author":"DC Fischer","year":"2011","unstructured":"Fischer DC, Jensen C, Rahn A, Salewski B, Kundt G, Behets GJ, D\u2019Haese P, Haffner D (2011) Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function. Pediatr Nephrol 26:111\u2013117","journal-title":"Pediatr Nephrol"},{"key":"1739_CR82","first-page":"534","volume":"29","author":"R Bergner","year":"2006","unstructured":"Bergner R, Diel IJ, Henrich D, Hoffmann M, Uppenkamp M (2006) Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 29:534\u2013540","journal-title":"Onkologie"},{"key":"1739_CR83","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","volume":"64","author":"GS Markowitz","year":"2003","unstructured":"Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D\u2019Agati VD (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281\u2013289","journal-title":"Kidney Int"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-010-1739-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-010-1739-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-010-1739-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-010-1739-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T06:14:50Z","timestamp":1610777690000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-010-1739-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":83,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1739"],"URL":"https:\/\/doi.org\/10.1007\/s00467-010-1739-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"31 October 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}